Editorial: overview of antiangiogenic therapies in hematological malignancies.
D
D
Ribatti
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006412:Hematopoietic Stem Cells / Q000378:metabolism; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors